We are live on ! Find out more
FLNA

Filana Therapeutics

87 hedge funds and large institutions have $154M invested in Filana Therapeutics in 2014 Q2 according to their latest regulatory filings, with 24 funds opening new positions, 30 increasing their positions, 21 reducing their positions, and 12 closing their positions.

New
Increased
Maintained
Reduced
Closed

5,000% more call options, than puts

Call options by funds: $612K | Put options by funds: $12K

100% more first-time investments, than exits

New positions opened: 24 | Existing positions closed: 12

43% more repeat investments, than reductions

Existing positions increased: 30 | Existing positions reduced: 21

16% more funds holding

Funds holding: 7587 (+12)

13% more capital invested

Capital invested by funds: $137M → $154M (+$17.2M)

0% more funds holding in top 10

Funds holding in top 10: 44 (0)

Holders
87
Holders Change
+12
Holders Change %
+16%
% of All Funds
2.5%
Holding in Top 10
4
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.11%
New
24
Increased
30
Reduced
21
Closed
12
Calls
$612K
Puts
$12K
Net Calls
+$600K
Net Calls Change
-$341K
Name Holding Trade Value Shares
Change
Change in
Stake
First Eagle Investment Management
1
First Eagle Investment Management
New York
$25.7M +$4.29M +115,855 +22%
VAM
2
Visium Asset Management
New York
$25M
MSP
3
Madison Street Partners
Colorado
$9.82M +$1.17M +31,674 +15%
GPP
4
Great Point Partners
Connecticut
$9.74M -$3.13M -84,717 -26%
BIT
5
BlackRock Institutional Trust
California
$8.66M +$328K +8,872 +4%
Vanguard Group
6
Vanguard Group
Pennsylvania
$7.11M +$394K +10,652 +6%
Deutsche Bank
7
Deutsche Bank
Germany
$5.75M -$34.3K -927 -0.6%
SC
8
Sophrosyne Capital
New York
$5.47M +$61.6K +1,664 +1%
BFA
9
BlackRock Fund Advisors
California
$5.46M +$4.44M +119,933 +766%
Dimensional Fund Advisors
10
Dimensional Fund Advisors
Texas
$4.38M +$780K +21,085 +24%
Acadian Asset Management
11
Acadian Asset Management
Massachusetts
$3.75M +$2.76M +74,647 +400%
GCM
12
Gruss Capital Management
New York
$3.45M -$739K -19,973 -19%
ICMC
13
Intrepid Capital Management (Connecticut)
Connecticut
$2.51M
D.E. Shaw & Co
14
D.E. Shaw & Co
New York
$2.45M +$414K +11,185 +23%
GIM
15
Granahan Investment Management
Massachusetts
$2.17M -$359K -9,696 -15%
State Street
16
State Street
Massachusetts
$2.11M +$1.79M +48,316 +1,215%
Renaissance Technologies
17
Renaissance Technologies
New York
$1.92M -$356K -9,628 -17%
PAMU
18
Pictet Asset Management (UK)
United Kingdom
$1.81M +$537K +14,514 +48%
TC
19
TFS Capital
Pennsylvania
$1.68M -$259K -6,989 -14%
Bank of New York Mellon
20
Bank of New York Mellon
New York
$1.57M +$1.12M +30,215 +343%
GF
21
Gabelli Funds
New York
$1.52M -$106K -2,857 -7%
BCM
22
Bridgeway Capital Management
Texas
$1.51M +$3.7K +100 +0.3%
Geode Capital Management
23
Geode Capital Management
Massachusetts
$1.15M +$143K +3,866 +16%
GI
24
GAMCO Investors
Connecticut
$863K -$159K -4,285 -17%
CAM
25
ClariVest Asset Management
California
$840K +$703 +19 +0.1%

FLNA Hedge Fund Activity: Q2 2014 in Review

87 of the 3,480 institutional investors tracked by Wall St. Rank reported a position in Filana Therapeutics (FLNA) for Q2 2014, worth a combined $154M — up 13% from $137M a quarter earlier.

Buyers outnumbered sellers: 24 funds opened new FLNA positions and 12 closed out — a net gain of 12 holders — while 30 added to existing stakes and 21 trimmed.

The largest buyer was BlackRock Fund Advisors, adding an estimated $4.44M. The largest seller was Broadfin Capital, exiting entirely with an estimated $4.29M sold.

  • 87 institutional investors held Filana Therapeutics (FLNA) as of Q2 2014, up from 75 in Q1 2014.
  • Funds reported $154M of Filana Therapeutics stock for Q2 2014, up 13% quarter-over-quarter.
  • 24 funds opened new Filana Therapeutics positions in Q2 2014 and 12 closed out, a net change of +12 holders.
  • The largest Filana Therapeutics buyer in Q2 2014 was BlackRock Fund Advisors, an estimated $4.44M added.
  • The largest Filana Therapeutics seller in Q2 2014 was Broadfin Capital, an estimated $4.29M sold.

Based on aggregated 13F filings for Q2 2014.